TG Therapeutics, Inc.
TGTX
$37.25
-$0.10-0.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 40.80% | 39.53% | 1,341.63% | 3,275.73% | 8,293.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.80% | 39.53% | 1,341.63% | 3,275.73% | 8,293.07% |
| Cost of Revenue | 172.34% | 392.68% | 805.45% | 2,014.69% | 5,232.45% |
| Gross Profit | 32.34% | 27.44% | 1,411.50% | 3,420.93% | 8,615.05% |
| SG&A Expenses | 25.75% | 28.44% | 43.70% | 66.81% | 75.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.76% | 27.11% | 27.05% | 40.49% | 8.90% |
| Operating Income | 103.21% | 97.33% | 160.37% | 129.67% | 110.70% |
| Income Before Tax | 95.94% | 46.40% | 154.53% | 124.69% | 106.59% |
| Income Tax Expenses | 466.92% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 84.52% | 44.55% | 154.47% | 124.44% | 106.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.52% | 44.55% | 154.47% | 124.44% | 106.39% |
| EBIT | 103.21% | 97.33% | 160.37% | 129.67% | 110.70% |
| EBITDA | 101.48% | 97.82% | 160.56% | 129.83% | 110.83% |
| EPS Basic | 100.50% | 51.41% | 152.95% | 123.31% | 105.50% |
| Normalized Basic EPS | 112.69% | 53.08% | 153.00% | 123.54% | 105.68% |
| EPS Diluted | 1,308.25% | 58.75% | 146.91% | 117.55% | 100.66% |
| Normalized Diluted EPS | 823.08% | 61.98% | 147.42% | 118.14% | 101.14% |
| Average Basic Shares Outstanding | 2.38% | 3.09% | 4.09% | 4.78% | 4.83% |
| Average Diluted Shares Outstanding | 7.89% | 6.03% | 9.08% | 7.15% | 7.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
